We’re tracking fast-moving developments in key cases covering President Donald Trump’s actions on immigration, transgender care and the federal workforce.
Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor. This article originally appeared here and ...